Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Bruno Sangro(Clinica Universidad de Navarra), Thomas Yau(University of Hong Kong), Todd S. Crocenzi(Providence Portland Medical Center), Masatoshi Kudo(Kindai University), Chiun Hsu(National Taiwan University Hospital), Tae‐You Kim(Seoul National University Hospital), Su-Pin Choo(National Cancer Centre Singapore), Jörg Trojan(Frankfurt Cancer Institute), Theodore H. Welling(University of Michigan), Tim Meyer(The Royal Free Hospital), Yoon‐Koo Kang(Asan Medical Center), Winnie Yeo(Chinese University of Hong Kong), Akhil Chopra(SingHealth Duke-NUS Academic Medical Centre), Jeffrey Anderson(Bristol-Myers Squibb (United States)), Christine Dela Cruz(Bristol-Myers Squibb (United States)), Lixin Lang(Bristol-Myers Squibb (United States)), Jaclyn Neely(Bristol-Myers Squibb (United States)), Hao Tang(Bristol-Myers Squibb (United States)), Homa Dastani(Bristol-Myers Squibb (United States)), Ignacio Melero(Centro de Investigación Biomédica en Red de Cáncer)
Cited by 4,296Open Access
Abstract
Related Papers
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.|New England Journal of Medicine|2012|12.6k